Barbara Hero

15.2k citations

170 papers · 8.3k indexed · 1 hit paper · h-index 48

Impact in

Neurology top 0.05%
- Neuroblastoma Research and Treatments
- Neurofibromatosis and Schwannoma Cases
Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism

Papers in ⓘ

Neurology 147
- Neuroblastoma Research and Treatments 143
- Neurofibromatosis and Schwannoma Cases 13
Molecular Biology 63
- Cancer therapeutics and mechanisms 38

Co-authors: Frank Berthold (108 shared papers)Thorsten Simon (60 shared papers)Matthias Fischer (28 shared papers)Frank Westermann (16 shared papers)Andreas Faldum (10 shared papers)Katherine K. Matthay (7 shared papers)Andrew D.J. Pearson (9 shared papers)Wendy B. London (8 shared papers)
Journals: Journal of Clinical Oncology (14 papers)Pediatric Blood & Cancer (13 papers)European Journal of Cancer (12 papers)Clinical Cancer Research (10 papers)Cancer (5 papers)
Partner nations: Germany United States United Kingdom

In The Last Decade

Barbara Hero

164 papers receiving 8.2k citations

Hit Papers

align trajectories log scale

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report 2008 · 1.3k citations

Peers

Countries citing papers authored by Barbara Hero

Since Specialization

Citations

This map shows the geographic impact of Barbara Hero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Hero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Hero more than expected).

Fields of papers citing papers by Barbara Hero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Hero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Hero. The network helps show where Barbara Hero may publish in the future.

Co-authors

The 25 scholars most cited alongside Barbara Hero, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barbara Hero Line = papers co-authored together Barbara Hero links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 170 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report Journal of Clinical Oncology ·Susan L. Cohn, Andrew D.J. Pearson, Wendy B. London, Tom Monclair, Peter F. Ambros, Garrett M. Brodeur, Andreas Faldum, Barbara Hero, Tomoko Iehara, David Machin, Véronique Mosseri, Thorsten Simon, Alberto Garaventa, Victoria Castel, Katherine K. Matthay Hit paper breakdown →	2008	1262
2	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis Clinical Cancer Research ·Ina Oehme, Hedwig E. Deubzer, Dennis Wegener, Diana Pickert, Jan-Peter Linke, Barbara Hero, Annette Kopp‐Schneider, Frank Westermann, Scott M. Ulrich, Andreas von Deimling, Matthias Fischer, Olaf Witt	2008	320
3	Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project Radiology ·Hervé J. Brisse, M. Beth McCarville, Claudio Granata, K Krug, Sandra L. Wootton‐Gorges, Kimio Kanegawa, Francesco Giammarile, Matthias Schmidt, Barry L. Shulkin, Katherine K. Matthay, Valerie Lewington, Sabine Sarnacki, Barbara Hero, Michio Kaneko, Wendy B. London, Andrew D.J. Pearson, Susan L. Cohn, Tom Monclair	2011	295
4	Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial The Lancet Oncology ·Frank Berthold, Joachim Boos, Stefan Burdach, R. Erttmann, Günter Henze, Johann Hermann, Thomas Klingebiel, Bernhard Kremens, Freimut H. Schilling, Martin Schrappe, Thorsten Simon, Barbara Hero	2005	272
5	Neuroblastoma Screening at One Year of Age New England Journal of Medicine ·Freimut H. Schilling, Claudia Spix, Frank Berthold, R. Erttmann, N. Fehse, Barbara Hero, Gisela Klein, Johannes Sander, K. Schwarz, J. Treuner, Ulrich Zorn, J. Michaelis	2002	238
6	Neuroblastoma: biology and molecular and chromosomal pathology The Lancet Oncology ·Manfred Schwab, Frank Westermann, Barbara Hero, Frank Berthold	2003	232
7	Metabolic activity and clinical features of primary ganglioneuromas Cancer ·Birgit Geoerger, Barbara Hero, D. Harms, Jochen Grebe, Klemens Scheidhauer, Frank Berthold	2001	231
8	Customized Oligonucleotide Microarray Gene Expression–Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification Journal of Clinical Oncology ·André Oberthuer, Frank Berthold, Patrick Warnat, Barbara Hero, Yvonne Kahlert, R. Spitz, Karen Ernestus, Rainer König, Stefan A. Haas, Roland Eils, Manfred Schwab, Benedikt Brors, Frank Westermann, Matthias Fischer	2006	198
9	Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97 Journal of Clinical Oncology ·Barbara Hero, Thorsten Simon, Ruediger Spitz, Karen Ernestus, Astrid Gnekow, Hans-Guenther Scheel-Walter, Dirk Schwabe, Freimut H. Schilling, G. Benz-Bohm, Frank Berthold	2008	191
10	Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas Genome biology ·Frank Westermann, Daniel Muth, Axel Benner, Tobias Bauer, Kai-Oliver Henrich, André Oberthuer, Benedikt Brors, Tim Beißbarth, Jo Vandesompele, Filip Pattyn, Barbara Hero, Rainer König, Matthias Fischer, Manfred Schwab	2008	183
11	Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma Cell Death and Disease ·H Kocak, Sandra Ackermann, Barbara Hero, Yvonne Kahlert, André Oberthuer, Dilafruz Juraeva, Frederik Roels, Jessica Theißen, Frank Westermann, Hedwig E. Deubzer, Volker Ehemann, Benedikt Brors, Margarete Odenthal, Frank Berthold, Matthias Fischer	2013	159
12	The Tumor-Associated Antigen *PRAME* Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome Clinical Cancer Research ·André Oberthuer, Barbara Hero, R. Spitz, Frank Berthold, Matthias Fischer	2004	149
13	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project Journal of Clinical Oncology ·Kieuhoa T. Vo, Katherine K. Matthay, John Neuhaus, Wendy B. London, Barbara Hero, Peter F. Ambros, Akira Nakagawara, Doug Miniati, Kate Wheeler, Andrew D.J. Pearson, Susan L. Cohn, Steven G. DuBois	2014	135
14	Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma Journal of Clinical Oncology ·Thorsten Simon, Barbara Hero, Andreas Faldum, Rupert Handgretinger, Martin Schrappe, D. Niethammer, Frank Berthold	2004	108
15	Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004 Cancer Letters ·Katherine K. Matthay, Franz Blaes, Barbara Hero, Dominique Plantaz, Pedro de Alarcón, Wendy G. Mitchell, Michael Pike, Vito Pistoia	2005	102
16	Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy BMC Cancer ·Thorsten Simon, Barbara Hero, Andreas Faldum, Rupert Handgretinger, Martin Schrappe, Thomas Klingebiel, Frank Berthold	2011	100
17	Vitamin B6 in Primary Hyperoxaluria I Clinical Journal of the American Society of Nephrology ·Heike Hoyer‐Kuhn, Sina Kohbrok, Ruth Volland, Jeremy Franklin, Barbara Hero, Bodo B. Beck, Bernd Höppe	2014	96
18	Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. PubMed ·Ruediger Spitz, Barbara Hero, Karen Ernestus, Frank Berthold	2003	95
19	Treatment and outcomes of patients with relapsed, high‐risk neuroblastoma: Results of German trials Pediatric Blood & Cancer ·Thorsten Simon, Frank Berthold, Arndt Borkhardt, Bernhard Kremens, Boris De Carolis, Barbara Hero	2010	94
20	Neuroblastoma Drugs ·Frank Berthold, Barbara Hero	2000	91

About Barbara Hero

Barbara Hero is a scholar working on Neurology, Molecular Biology, Cancer Research, Surgery and Oncology, having authored 170 papers that have together received 8.3k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (143 papers), Cancer, Hypoxia, and Metabolism (55 papers), Cancer therapeutics and mechanisms (38 papers), Adrenal and Paraganglionic Tumors (21 papers), Lung Cancer Research Studies (20 papers), Neuroendocrine Tumor Research Advances (16 papers), Neurofibromatosis and Schwannoma Cases (13 papers) and Glioma Diagnosis and Treatment (11 papers). The work is most often cited by research in Neurology (6.3k citations), Cancer Research (2.5k citations), Genetics (728 citations), Oncology (1.6k citations) and Molecular Biology (3.7k citations). Barbara Hero has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Frank Berthold, Thorsten Simon, Matthias Fischer, Frank Westermann, Andreas Faldum, Katherine K. Matthay, Andrew D.J. Pearson, Wendy B. London, Susan L. Cohn and Tom Monclair. Their work appears in journals such as Journal of Clinical Oncology, Pediatric Blood & Cancer, European Journal of Cancer, Clinical Cancer Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact